

Sequence Comparison

Page 2

under expression of the polypeptides or the expression of inactive polypeptides. The nucleic acids and the polypeptides they encode may be used according to standard gene therapy protocols to treat diseases associated with inappropriate TANGO expression by supplementing a patient's own production of the polypeptides or to rectify mutations that may result in expression of an abnormally active polypeptide. The polypeptides may also be used to identify active polypeptides and antagonists of TANGO expression and activity which may be used to modulate TANGO related processes and diseases. The polypeptides are particularly useful for use as antigens for producing antibodies to TANGO proteins which may be used for inhibiting the activity of TANGO proteins. They may also be used to detect and quantify the presence of TANGO proteins in samples and therefore identify patients in whom the protein is over- or under-expressed. This sequence represents the human TANGO 134 protein described in the method of the invention

XX Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 3; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MATLWGLRLGSLLSLSCLALSVLILAQLSDAANKFEDVCKICPPYKENGHIYNN 60
Db 1 MATLWGLRLGSLLSLSCLALSVLILAQLSDAANKFEDVCKICPPYKENGHIYNN 60
QY 61 ISQKDCDLHVVEPVRGPDVAYCLRCCKYERSSVTIKVIIYLSILGLLLYV 120
Db 61 ISQKDCDLHVVEPVRGPDVAYCLRCCKYERSSVTIKVIIYLSILGLLLYV 120
QY 121 YLTLPKRLRLEFCHLAQLQSDDDGDKQFFANAHVDLAESRANVKNKVEYAQRWK 180
Db 121 YLTLPKRLRLEFCHLAQLQSDDDGDKQFFANAHVDLAESRANVKNKVEYAQRWK 180
QY 181 LQVQRKSVFDRHWLVS 198
Db 181 LQVQRKSVFDRHWLVS 198

RESULT 2

AAV66762
ID AAV66762 standard; protein; 198 AA.

XX
AC AAV66762;

XX
DT 05-APR-2000 (first entry)

XX
DE Membrane-bound protein PRO1375.

XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
pharmacological; receptor immunoadhesin; gene mapping.

XX
OS Homo sapiens.

XX
PN WO9963088-A2.

XX
PD 03-DEC-1999.

XX
PF 02-JUN-1999; 99WO-US012352.

XX
PR 02-JUN-1999; 98US-0087607P.

XX
PR 02-JUN-1999; 98US-0087609P.

XX
PR 02-JUN-1999; 98US-0087759P.

XX
PR 03-JUN-1999; 98US-0087877P.

XX
PR 04-JUN-1999; 98US-0088031P.

XX
PR 04-JUN-1999; 98US-0088032P.

XX
PR 04-JUN-1999; 98US-0088033P.

XX
PR 04-JUN-1999; 98US-0088030P.

XX
PR 04-JUN-1999; 98US-0088326P.

XX
PR 05-JUN-1999; 98US-0088167P.

XX
PR 05-JUN-1999; 98US-0088202P.

Sequence Comparison

PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088872P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090242P.
PR 22-JUN-1998; 98US-0090254P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090353P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090674P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 01-JUL-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091624P.
PR 02-JUL-1998; 98US-0091629P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091648P.
PR 02-JUL-1998; 98US-0091673P.

Sequence Comparison

07-JUL-1998; 98US-0091978P;
07-JUL-1998; 98US-0091982P;
09-JUL-1998; 98US-0092182P;
10-JUL-1998; 98US-0092472P;
20-JUL-1998; 98US-0093339P;
04-AUG-1998; 98US-0094851P;
04-AUG-1998; 98US-0095382P;
04-AUG-1998; 98US-0095501P;
04-AUG-1998; 98US-0095502P;
04-AUG-1998; 98US-0095518P;
04-AUG-1998; 98US-0095521P;
04-AUG-1998; 98US-0095525P;
10-AUG-1998; 98US-0095916P;
10-AUG-1998; 98US-0095929P;
10-AUG-1998; 98US-0096012P;
11-AUG-1998; 98US-0096143P;
12-AUG-1998; 98US-0096146P;
17-AUG-1998; 98US-0096529P;
17-AUG-1998; 98US-0096575P;
17-AUG-1998; 98US-0096766P;
17-AUG-1998; 98US-0096768P;
17-AUG-1998; 98US-0096773P;
17-AUG-1998; 98US-0096791P;
17-AUG-1998; 98US-0096867P;
17-AUG-1998; 98US-0096891P;
17-AUG-1998; 98US-0096894P;
17-AUG-1998; 98US-0096895P;
17-AUG-1998; 98US-0096896P;
17-AUG-1998; 98US-0096897P;
18-AUG-1998; 98US-0096949P;
18-AUG-1998; 98US-0096950P;
18-AUG-1998; 98US-0096959P;
18-AUG-1998; 98US-0096960P;
18-AUG-1998; 98US-0097022P;
19-AUG-1998; 98US-0097141P;
20-AUG-1998; 98US-0097218P;
24-AUG-1998; 98US-0097651P;
24-AUG-1998; 98US-0097851P;
26-AUG-1998; 98US-0097852P;
26-AUG-1998; 98US-0097854P;
26-AUG-1998; 98US-0097855P;
26-AUG-1998; 98US-0097971P;
26-AUG-1998; 98US-0097974P;
26-AUG-1998; 98US-0097978P;
26-AUG-1998; 98US-0097979P;
26-AUG-1998; 98US-0097986P;
31-AUG-1998; 98US-0098014P;
16-SEP-1998; 98US-0098525P;
12-JAN-1999; 98US-0100634P;
99US-0115565P;

(GETH) GENENTECH INC.

Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
Wood WI, Yuan J;

WPI; 2000-072883/06.
N-PSDB; AA265108.

Membrane-bound proteins and related nucleotide sequences.

Clam 12; Fig 300; 822pp; English.

The invention provides membrane-bound PRO polypeptides and polynucleotides encoding them. The PRO sequences of the invention were identified based on extracellular domain homology screening. The PRO sequences have homology with proteins including LBL receptors, TIE ligands and various enzymes. The membrane-bound proteins and receptor molecules are useful as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be used as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The PRO encoding sequences

are useful as hybridization probes, in chromosome and gene mapping and in the generation of antisense RNA and DNA. PRO nucleic acid sequences will also be useful for the preparation of PRO polypeptides, especially by recombinant techniques

Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 3; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104; Indels 0; Gaps 0;
Matches 198; Conservative 0; Mismatches 0;

QY 1 NATLWGLLRGLSLSLALSVLLLAQLSDAAKFNEDVRCKICPPYKENGSHYNN 60
DB 1 NATLWGLLRGLSLSLALSVLLLAQLSDAAKFNEDVRCKICPPYKENGSHYNN 60
QY 61 ISKQDCCLHVEPMPVGRPDVEAYCLRCECKYEERSVTIKVIIYLSILGLLLMY 120
DB 61 ISKQDCCLHVEPMPVGRPDVEAYCLRCECKYEERSVTIKVIIYLSILGLLLMY 120
QY 121 YLTVEPILKRLFGHAQLIQSDDDIGDHPFANAHDLARSANVANKVEYAQRWK 190
DB 121 YLTVEPILKRLFGHAQLIQSDDDIGDHPFANAHDLARSANVANKVEYAQRWK 190
QY 131 LQVQQRKSVFDRHVLS 198
DB 131 LQVQQRKSVFDRHVLS 198

RESULT 3

AA87231
ID AA87231 standard; protein; 198 AA.

XX
AC AA87231;

DT 11-MAY-2000 (first entry)

DE Human signal peptide containing protein HSP8-8 SEQ ID NO:8.

XX Human; signal peptide-containing protein; HSP8; diagnosis; cancer;
XX inflammation; cardiovascular disease; anticancer; anti-inflammatory;
XX antimicrobial; neuroprotective; cardiovascular; hepatotropic;
XX antitubercular; gene therapy; cell proliferation; neurological disorder;
XX reproductive disorder; developmental disorder; arteriosclerosis;
XX cirrhosis; peptidosis; acquired immune deficiency syndrome; anaemia;
XX asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
XX Parkinson's disease; Huntington's disease; ovulatory defect;
XX muscular dystrophy.

OS Homo sapiens.

XX WO20000610-A2.

XX 06-JAN-2000.

XX 25-JUN-1999; 99WO-US014484.

XX 26-JUN-1998; 98US-0090762P.

XX 31-JUL-1998; 98US-0094983P.

XX 01-OCT-1998; 98US-0102866P.

XX 11-DEC-1998; 98US-0112129P.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;

XX Akerblom EB, Au-Yang J, Yue H, Patterson C, Reddy R, Hillman JL;

XX Bandman O;

XX WPI; 2000-160673/14.

XX N-PSDB; AA298116.

XX New human signal peptide-containing proteins useful in treatment,
XX prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
XX disease.

Sequence Comparison

See page 4

sequence, ison D, compare

Query Match	100.0%	Score 1031	DB 3	Length 198						
Best Local Similarity	100.0%	Pred. NO. 1.4e-104								
Matches 198	Conservative 0	Mismatches 0	Indels 0	Gaps 0						
QY	1	MATLWGGLRLGLSLSLCLALS	VLLLAQ	SDAAK	FEDVRK	KCICPPYK	ENSGH	YINX	60	
Db	1	MATLWGGLRLGLSLSLCLALS	VLLLAQ	SDAAK	FEDVRK	KCICPPYK	ENSGH	YINX	60	
QY	61	ISOKDCCCLHVPMPV	RGVPEAY	CLRCCKEY	ESSVTIK	VTIIYV	SLGILL	LYMV	120	
Db	61	ISOKDCCCLHVPMPV	RGVPEAY	CLRCCKEY	ESSVTIK	VTIIYV	SLGILL	LYMV	120	
QY	121	YLTVLPEPIKLRAL	FQHAQLIS	DDDDIS	GDHQP	FANAH	DVLARS	GRANV	LNKVEYAQ	RVK 180
Db	121	YLTVLPEPIKLRAL	FQHAQLIS	DDDDIS	GDHQP	FANAH	DVLARS	GRANV	LNKVEYAQ	RVK 180
QY	181	LQVQEQRKSV	PDFRHHV	VL 198						
Db	181	LQVQEQRKSV	PDFRHHV	VL 198						

sequence comparison

```

Hesc Local Similarity 100.04; Pred. NO. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MATYAGGLRLGSLSLISCSLALSVLLLAQLSDAAKNFEDVRCKICPPYKENSCHIYNNK 60
Db 1 MATYAGGLRLGSLSLISCSLALSVLLLAQLSDAAKNFEDVRCKICPPYKENSCHIYNNK 60
QY 61 ISQKQDCDCLHVVEMFVRGPDVEAYCLRCCKYERSSVTKVTIIYLSILGLLLLYW 120
Db 61 ISQKQDCDCLHVVEMFVRGPDVEAYCLRCCKYERSSVTKVTIIYLSILGLLLLYW 120
QY 121 YLTVEPILKRLFGHQAQLQSDDDIDGDHPFPANAHVDVLARSSRANVLNKVEYACQWK 180
Db 121 YLTVEPILKRLFGHQAQLQSDDDIDGDHPFPANAHVDVLARSSRANVLNKVEYACQWK 180
QY 181 LQVQEQKRSVFDHRVTVLS 198
Db 181 LQVQEQKRSVFDHRVTVLS 198

RESULT 5
AAM93740
ID AAM93740 standard: protein: 198 AA

```

RESULT 5
AAM93740
ID AAM9

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2004, 08:19:27 : Search time 60 Seconds
(without alignments)

932.407 Million cell updates/sec

Title: US-09-997-573-418

Perfect score: 1031
Sequence: 1 MATWGLLRLSLSLSL.....WKLOVQKSVFDRHVLS 198

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_29Jan04:*

- 1: Geneseqp1980s:*
- 2: Geneseqp1990s:*
- 3: Geneseqp2000s:*
- 4: Geneseqp2001s:*
- 5: Geneseqp2002s:*
- 6: Geneseqp2003as:*
- 7: Geneseqp2003bs:*
- 8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1031	100.0	198	3 AAY88275	Aay88275 Human TAN
2	1031	100.0	198	3 AAY66762	Aay66762 Membrane-
3	1031	100.0	198	3 AAY87231	Aay87231 Human sig
4	1031	100.0	198	3 AAY78807	Aay78807 Hydrophob
5	1031	100.0	198	3 AAM93740	Aam93740 Human pol
6	1031	100.0	198	4 AAB50966	Aab50966 Human PRO
7	1031	100.0	198	4 AAB50120	Aab50120 Human imm
8	1031	100.0	198	4 AAM38735	Aam38735 Human pol
9	1031	100.0	198	4 AAB50925	Aab50925 Human PRO
10	1031	100.0	198	4 AAB52855	Aab52855 Human PRO
11	1031	100.0	198	5 ABP61428	Abp61428 Human NF-
12	1031	100.0	198	6 ABUS8100	Abus8100 Human PRO
13	1031	100.0	198	6 ABUS9178	Abus9178 Novel hum
14	1031	100.0	198	6 ABUS2690	Abus2690 Human sec
15	1031	100.0	198	6 ABUS0609	Abus0609 Human sec
16	1031	100.0	198	6 ABU13991	Abu13991 Human PRO
17	1031	100.0	198	6 ABU72576	Abu72576 Novel hum
18	1031	100.0	198	6 ABU71432	Abu71432 Human neo
19	1031	100.0	198	6 ABUS9325	Abus9325 Human sec
20	1031	100.0	198	6 ABUS2622	Abus2622 Human PRO
21	1031	100.0	198	6 ABUS5031	Abus5031 Human sec
22	1031	100.0	198	6 ABUS2409	Abus2409 Novel hum
23	1031	100.0	198	6 ABUS9474	Abus9474 Novel hum
24	1031	100.0	198	6 ABUS2240	Abus2240 Novel hum
25	1031	100.0	198	6 ABU10946	Abu10946 Human PRO

26	1031	100.0	198	6 ABUS1698	Abus1698 Novel hum
27	1031	100.0	198	6 ABUS8637	Abus8637 Human sec
28	1031	100.0	198	6 ABO34151	Abos34151 Human PRO
29	1031	100.0	198	6 ADA37929	Ada37929 Human sec
30	1031	100.0	198	6 ADA21615	Ada21615 Human sec
31	1031	100.0	198	6 ADA10402	Ada10402 Human PRO
32	1031	100.0	198	6 ADA17946	Ada17946 Human PRO
33	1031	100.0	198	6 ADA28054	Ada28054 Human sec
34	1031	100.0	198	6 ADA34634	Ada34634 Human sec
35	1031	100.0	198	6 ADA38859	Ada38859 Human sec
36	1031	100.0	198	6 ADA92980	Ada92980 Human sec
37	1031	100.0	198	7 ABO53237	Abos53237 Human sec
38	1031	100.0	198	7 ADA22541	Ada22541 Human sec
39	1031	100.0	198	7 ABO22607	Abos22607 Human sec
40	1031	100.0	198	7 ADA06707	Ada06707 Human sec
41	1031	100.0	198	7 ADA39400	Ada39400 Human sec
42	1031	100.0	198	7 ADA36426	Ada36426 Human PRO
43	1031	100.0	198	7 ADC57898	Adc57898 Human PRO
44	1031	100.0	198	7 ADC55562	Adc55562 Human PRO
45	1031	100.0	198	7 ADC12129	Adc12129 Human sec

ALIGNMENTS

Sequence comparison
1A

RESULT 1
AAY88275
ID AAY88275 standard; protein; 198 AA.
AC AAY88275;
DI 16-OCT-2000 (first entry)
DE Human TANGO 184 protein.

XX TANGO 180; TANGO 181; TANGO 182; TANGO 183; TANGO 184; TANGO 185;
XX TANGO 186; TANGO 188; TANGO 189; TANGO 215; TANGO 187; human; murine;
XX secreted protein; transmembrane protein; gene therapy; vaccine;
XX diagnosis; treatment; detection.
XX Homo sapiens.
OS
XX
PN WC2000016904-A2.
PD
XX 06-APR-2000.
XX 30-SEP-1999; 99WO-US022817.
XX 30-SEP-1998; 98US-00164220.
XX 02-OCT-1998; 98US-00164169.
(MILL-) MILLENNIUM BIOTHERAPEUTICS INC.
XX Barnes TM;
XX WPI; 2000-293144/25.
XX N-PSDB; AAA39941, AAA39942.
XX Isolated nucleic acids encoding TANGO polypeptides useful for preventing,
XX diagnosing and treating diseases associated with inappropriate protein
XX expression.
XX Claim 9; Fig 9; 249pp; English.

This invention describes novel human and murine nucleic acids encoding TANGO polypeptides (which are either wholly secreted or transmembrane proteins) which can be used for gene therapy and/or vaccination. The peptides are designated TANGO 180 to TANGO 189 and TANGO 215. The nucleic acids may be used to produce TANGO 180 to TANGO 189 and TANGO 215 polypeptides according to standard recombinant DNA methodologies. They may also be used to detect and quantify the presence of TANGO nucleic acids in a sample and therefore identify or diagnose diseases associated with inappropriate TANGO expression (e.g. diseases related to over or

See page 2

Sequence Comparison

```
XX AA093740;
XX AC
XX DT 06-NOV-2001 (first entry)
XX DE Human polypeptide, SEQ ID NO: 3711.
XX KW Human; full length cDNA; cDNA synthesis; oligo-capping.
XX OS Homo sapiens.
XX PN EP1130094-A2.
XX PD 05-SEP-2001.
XX PF 07-JUL-2000; 2000EP-00114089.
XX PR 08-JUL-1999; 99JP-00194486.
XX PR 11-JAN-2000; 2000JP-00118774.
XX PR 02-MAY-2000; 2000JP-00183765.
XX PA (HELI-) HELIX RES INST.
XX PI Ota T, Nishikawa T, Isogai T, Hayaashi K, Ishii S, Kawai Y,
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX WPI. 2001-524255/58.
XX DR N-PSDB; AAK94692.
XX PR 830 Primers useful for synthesizing full length cDNA clones and their use
PT in genetic manipulation.
XX PS Claim 8; SEQ ID NO 3711; 1380pp + Sequence Listing; English.
XX CC The invention relates to primers for synthesizing full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been isolated
CC and nucleotide sequences of 5' and 3' ends of the cDNA molecules have
CC been determined. Primers for synthesizing the full length cDNA are useful
CC for clarifying the function of the protein encoded by the cDNA. The full
CC length clones were obtained by construction of full length enriched cDNA
CC libraries that were synthesised by the oligo-capping method. The primers
CC enable the production of the full length cDNA easily without any special
CC methods. The present sequence is a polypeptide encoded by a full length
CC human cDNA of the invention. Note: The sequence data for this patent did
CC not form part of the printed specification, but was obtained in CD-ROM
CC format directly from EPO
XX SQ Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 4; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MATLGGILRLGSLLSCLSLVLLAQLSDAAKNFEDVRCKICPPYKENSCHYKN 60
DB 1 MATLGGILRLGSLLSCLSLVLLAQLSDAAKNFEDVRCKICPPYKENSCHYKN 60
QY 61 ISQKDCDLHVVPEPVRGPDVEAYCLRCCKVEERSSTIKVTIIIVLSILGLLLYV 120
DB 61 ISQKDCDLHVVPEPVRGPDVEAYCLRCCKVEERSSTIKVTIIIVLSILGLLLYV 120
QY 121 YLTLPVPIKRLFLGHAQLISDDDDIGDHQPFANAHVDLARSRSRANVINKVEYAQRWK 180
DB 121 YLTLPVPIKRLFLGHAQLISDDDDIGDHQPFANAHVDLARSRSRANVINKVEYAQRWK 180
QY 181 LQVQQRKSVFDRHVLS 198
DB 181 LQVQQRKSVFDRHVLS 198

RESULT 6
AAB50966
ID AAB50966 standard; protein; 198 AA.
```

```
XX AAB50966;
XX AC
XX DT 21-MAR-2001 (first entry)
XX DE Human PRO1375 protein.
XX KW Human; PRO; cytostatic; neotropic; neuroprotective; respiratory general;
XX antiinflammatory; antiangiogenic; immunosuppressive; immunostimulant;
XX PRO agonist; cancer; inflammatory disorder; immunological disorder.
XX OS Homo sapiens.
XX PN WO2000073348-A2.
XX PD 07-DEC-2000.
XX PF 30-MAY-2000; 2000WO-US014941.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 22-JUN-1999; 99US-0140650P.
XX PR 23-JUN-1999; 99US-014037P.
XX PR 20-JUL-1999; 99US-014758P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 29-OCT-1999; 99US-0162506P.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 03-DEC-1999; 99US-0170362P.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 06-JAN-2000; 2000WO-US000376.
XX PR 11-FEB-2000; 2000WO-US003565.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 02-MAR-2000; 2000WO-US004342.
XX PR 03-MAR-2000; 2000US-0187202P.
XX PR 10-MAR-2000; 2000WO-US006319.
XX PR 15-MAR-2000; 2000WO-US006884.
XX PR 17-MAY-2000; 2000WO-US008439.
XX PR 17-MAY-2000; 2000WO-US013705.
XX PA (GSH ) GENENTECH INC.
XX PI Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W, Kabakoff RC,
PI Shelton DL, Smith V, Watanabe CK, Wood WI;
XX WPI; 2001-016509/02.
XX DR N-PSDB; AAC91568.
XX PT Twenty eight nucleic acids encoding PRO polypeptides which are useful for
XX treating various tumors, e.g. breast cancer, and other inflammatory,
XX angiogenic and immunological disorders.
XX PS Claim 31, Fig 32; 188pp; English.
XX CC The present sequence is one of twenty eight novel PRO polypeptides. The
XX PRO polypeptides and their agonists, including antibodies, peptides, and
XX small molecule agonists, may be used to treat various tumors, e.g.,
XX cancers such as breast cancer, ovarian cancer, renal cancer, colorectal
XX cancer, uterine cancer, prostate cancer, lung cancer, bladder cancer,
XX central nervous system cancer, melanoma or leukaemia. They are also
XX useful for treating other disorders such as neuronal, glial, astrocytal,
XX hypothalamic and other glandular, macrophagal, epithelial, stromal and
XX blastocoealic disorders, and inflammatory, angiogenic and immunological
XX disorders
XX SQ Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 4; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```